In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of X4 Pharmaceuticals Inc (NASDAQ: XFOR) closed at $1.15 in the last session, up 6.48% from day before closing price of $1.08. In other words, the price has increased by $6.48 from its previous closing price. On the day, 2.82 million shares were traded. XFOR stock price reached its highest trading level at $1.16 during the session, while it also had its lowest trading level at $1.08.
Ratios:
We take a closer look at XFOR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.34 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 1.14 whereas as Long-Term Debt/Eq ratio is at 1.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 11 ’24 when Mostafa Adam S. sold 52,500 shares for $0.88 per share. The transaction valued at 46,347 led to the insider holds 0 shares of the business.
Ragan Paula sold 49,678 shares of XFOR for $43,856 on Mar 11 ’24. The President and CEO now owns 765,068 shares after completing the transaction at $0.88 per share. On Mar 11 ’24, another insider, DiBiase Mary, who serves as the Chief Operating Officer of the company, sold 15,409 shares for $0.88 each. As a result, the insider received 13,591 and left with 291,752 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 193128688 and an Enterprise Value of 137193456.
Stock Price History:
The Beta on a monthly basis for XFOR is 0.42, which has changed by -0.33742332 over the last 52 weeks, in comparison to a change of 0.22379243 over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $2.58, while it has fallen to a 52-week low of $0.57. The 50-Day Moving Average of the stock is 0.14%, while the 200-Day Moving Average is calculated to be 10.15%.
Shares Statistics:
According to the various share statistics, XFOR traded on average about 3.12M shares per day over the past 3-months and 5945660 shares per day over the past 10 days. A total of 167.43M shares are outstanding, with a floating share count of 122.08M. Insiders hold about 27.30% of the company’s shares, while institutions hold 35.45% stake in the company. Shares short for XFOR as of 1713139200 were 12264810 with a Short Ratio of 3.93, compared to 1710460800 on 14222812. Therefore, it implies a Short% of Shares Outstanding of 12264810 and a Short% of Float of 7.32.
Earnings Estimates
The stock of X4 Pharmaceuticals Inc (XFOR) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of -$0.16 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.22, while EPS last year was -$0.16. The consensus estimate for the next quarter is -$0.05, with high estimates of $0.36 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.08 and -$0.76 for the fiscal current year, implying an average EPS of -$0.51. EPS for the following year is -$0.46, with 7.0 analysts recommending between -$0.06 and -$0.71.
Revenue Estimates
Based on 7 analysts’ estimates, the company’s revenue will be $50.55M in the next fiscal year. The high estimate is $163.1M and the low estimate is $4.27M.
